Docoh
Loading...

MYGN Myriad Genetics

News

Pro users get this 30m faster
Myriad Genetics Insider Sold Over $492K In Company Stock
28 Sep 21
News, Insider Trades, Trading Ideas
Nicole Lambert, Corporate Officer at Myriad Genetics (NASDAQ:MYGN), made a large insider sell on September 27, according to a new SEC filing.
Illumina Partners with Merck to Develop and Commercialize Companion Diagnostic and Research Tests for Use in Identifying Specific Cancer Mutations
7 Sep 21
News, Contracts, FDA
Illumina, Inc. (NASDAQ:ILMN) and Merck (known as MSD outside the United States and Canada) today announced a partnership to develop and commercialize tests that identify genetic mutations used in the
4 Stocks Insiders Are Buying
9 Aug 21
News, Insider Trades, Intraday Update, Markets, Trading Ideas
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
5 Aug 21
Biotech, Earnings, News, Penny Stocks, Guidance, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4)
Stocks That Hit 52-Week Highs On Wednesday
4 Aug 21
News, Intraday Update, Markets, Movers, Trading Ideas
Before 10 a.m. ET Wednesday, 138 stocks hit new 52-week highs.
The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
4 Aug 21
Biotech, Earnings, News, Penny Stocks, Guidance, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3)
75 Biggest Movers From Yesterday
4 Aug 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers
What's Up With Myriad Genetics Shares Trading Higher Tuesday?
3 Aug 21
Movers, Trading Ideas
Myriad Genetics, Inc. (NASDAQ: MYGN) shares are trading higher by 12.4% at $34.68 Tuesday afternoon after the company reported better-than-expected fourth-quarter EPS and sales results.
48 Stocks Moving In Tuesday's Mid-Day Session
3 Aug 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) shares jumped 64.4% to $7.15 after a Form 4 filing from the company showed 10% shareholder Retail Ecommerce Ventures purchased 237,500 shares of Wilhelmina.
Stocks That Hit 52-Week Highs On Tuesday
3 Aug 21
News, Intraday Update, Markets, Movers, Trading Ideas
During Tuesday's morning trading, 101 companies set new 52-week highs.
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
3 Aug 21
Biotech, Earnings, News, Penny Stocks, Guidance, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 2)
Myriad Genetics Q4 Adj. EPS $0.12 Beats $(0.07) Estimate, Sales $189.40M Beat $166.73 Estimate
3 Aug 21
Earnings, News
Myriad Genetics (NASDAQ:MYGN) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $(0.07) by 271.43 percent. This is a 138.71 percent increase over losses of $(0.31) per share from
Earnings Scheduled For August 3, 2021
3 Aug 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter. • Stellantis (NYSE:STLA) is expected to report earnings for its second quarter.
Myriad Genetics Expands Access to Genetic Testing with Launch of First Polygenic Breast Cancer Risk Assessment Score Validated for Women of All Ancestries
2 Aug 21
News
Advancing its mission to expand access to genetic testing, Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today launched a new version of its market-leading MyRisk Hereditary
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
1 Aug 21
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, IPOs, Top Stories, General
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies.

Press releases

Pro users get this 30m faster
Americans' anxiety impacted by the ongoing pandemic, yet 1 in 5 say they won't seek treatment according to the GeneSight® Mental Health Monitor nationwide survey
11 Oct 21
Health Care, Analyst Ratings, Press Releases
SALT LAKE CITY, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Many Americans are experiencing anxiety symptoms as a result of the pandemic. Yet, one in five say they won't seek treatment for mental health conditions and others say
Bragar Eagel & Squire is Investigating Certain Officers and Directors of CarLotz, Myriad Genetics, and AMC Entertainment on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
29 Sep 21
News, Legal, Press Releases
NEW YORK, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors of CarLotz, Inc. (NASDAQ:LOTZ), Myriad
Myriad Genetics Completes Sale of Myriad Autoimmune's Vectra Testing Business to LabCorp
13 Sep 21
M&A, News, Health Care, Press Releases
SALT LAKE CITY, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced that it has completed the sale of select operating assets and
Only 8% of people remain hopeful after depression medication fails them, according to GeneSight® Mental Health Monitor nationwide survey
8 Sep 21
Health Care, Press Releases
SALT LAKE CITY, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Depression medication trial and error is far too common – and may result in additional mental health challenges. When people with depression take a medication
Illumina Partners with Merck to Develop and Commercialize Companion Diagnostic and Research Tests for Use in Identifying Specific Cancer Mutations
7 Sep 21
News, Contracts, Press Releases
SAN DIEGO, Sept. 7, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) and Merck (known as MSD outside the United States and Canada) today announced a partnership to develop and commercialize tests that identify genetic
Theragnostics Strengthens Board of Directors with Key Appointments
4 Aug 21
Press Releases
LONDON, Aug. 4, 2021 /PRNewswire/ -- Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, announces today the appointments of Dr Dennis Langer and Professor Ken
Myriad Genetics Delivers Strong Revenue and Earnings Growth in June 2021 Quarter, Continues to Execute on Strategic Growth & Transformation Plans
3 Aug 21
Earnings, News, Press Releases
SALT LAKE CITY, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced financial results for its second quarter ended June 30, 2021
Myriad Genetics Expands Access to Genetic Testing with Launch of First Polygenic Breast Cancer Risk Assessment Score Validated for Women of All Ancestries
2 Aug 21
Health Care, Press Releases, General
Myriad's MyRisk® Hereditary Cancer test with RiskScore® provides a breast cancer risk assessment for all women not previously diagnosed with breast cancer, regardless of ancestryMyRisk with RiskScore is an
Myriad Genetics to Release Second Quarter Financial Results on August 3, 2021
28 Jul 21
News, Press Releases
SALT LAKE CITY, July 28, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced that it will hold its quarterly earnings conference call for
New research reveals most Americans can't identify the symptoms of depression
28 Jul 21
Analyst Ratings, Press Releases
SALT LAKE CITY, July 28, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced results from a recent nationwide poll, the GeneSight®
Myriad Genetics Supports New ACMG Recommendation Statement on Increasing Access to Carrier Screening for All Ethnicities
21 Jul 21
Biotech, Health Care, Press Releases, General
SALT LAKE CITY, July 21, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced its support for a new recommendation statement by the American